🇺🇸 FDA
Pipeline program

ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011

CLEE011X2107

Phase 2 small_molecule active

Quick answer

ALPELISIB, RIBOCICLIB, LETROZOLE, LEE011, ALPELISIB, LEE011 for Advanced HR+ breast cancer is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Advanced HR+ breast cancer
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials